Abstract: Oxidative stress refers to the imbalance between oxidation and antioxidant activity in the body. Oxygen is reduced by electrons as part of normal metabolism leading to the formation of various reactive oxygen species (ROS). ROS are the main cause of oxidative stress and can be assessed through direct detection. Oxidative stress is a double-edged phenomenon in that it has protective mechanisms that help to destroy bacteria and pathogens, however, increased ROS accumulation can lead to host cell apoptosis and damage. Glioma is one of the most common malignant tumors of the central nervous system and is characterized by changes in the redox state. Therapeutic regimens still encounter multiple obstacles and challenges. Glioma occurrence is related to increased free radical levels and decreased antioxidant defense responses. Oxidative stress is particularly important in the pathogenesis of gliomas, indicating that antioxidant therapy may be a means of treating tumors. This review evaluates oxidative stress and its effects on gliomas, describes the potential targets and therapeutic drugs in detail, and clarifies the effects of radiotherapy and chemotherapy on oxidative stress. These data may provide a reference for the development of precise therapeutic regimes of gliomas based on oxidative stress.
Introduction
Gliomas, particularly glioblastoma (GBM), represent the most aggressive primary tumors of the central nervous system. Despite advancements in standard care, prognosis remains poor due to the tumor's adaptive mechanisms. Central to this adaptation is redox homeostasis. Glioma cells maintain a delicate balance between high reactive oxygen species (ROS) production—which drives DNA mutations and growth—and upregulated antioxidant defense systems that protect the tumor from its own toxic environment. This review synthesizes current knowledge on these molecular mechanisms to identify therapeutic vulnerabilities.
The ROS Threshold and Cellular Fate
ROS levels in gliomas follow a "Goldilocks" principle. While low levels facilitate signaling and proliferation, exceeding a specific threshold can trigger programmed cell death pathways such as apoptosis or parthanatos.
As illustrated in Figure 1, ROS can be generated through endogenous pathways like the mitochondrial respiratory chain and NADPH oxidase, or exogenous triggers such as radiation and chemotherapy. When the balance tips, ROS accumulation leads to DNA damage and cell death.
Molecular Modulators of Redox Balance
Several key proteins regulate this balance. Pyruvate kinase M2 (PKM2), beyond its role in glycolysis, translocates to the nucleus under oxidative stress to stabilize anti-apoptotic proteins like Bcl2. However, the most critical regulator is the Nrf2 pathway.
The Nrf2/KEAP1/ARE pathway (Figure 6) serves as a "master shield" for gliomas. Tumors hijack this system to neutralize oxidative damage from therapies. Under stress, Nrf2 is released from its inhibitor KEAP1, enters the nucleus, and activates antioxidant response elements (ARE), promoting survival and resistance.
Therapeutic Strategies and Phytocompounds
Targeting these pathways offers a route to sensitize gliomas to treatment. Research has identified several genes—DGAT1, PTPN2, and OSMR—whose high expression correlates with poor survival due to their roles in managing oxidative stress.
Natural phytocompounds are emerging as "redox tippers." Unlike simple antioxidants, compounds like Shikonin and Celastrol induce ROS overproduction specifically in cancer cells. Other candidates include Silibinin, which triggers autophagy-mediated death, and Atovaquone, which sensitizes tumors to radiation by alleviating hypoxia.
Challenges and Future Directions
Translating these findings into clinical practice faces significant hurdles. The blood-brain barrier (BBB) limits the delivery of many promising compounds. Furthermore, the dynamic nature of oxidative stress requires precise timing and dosage to avoid damaging healthy neural tissue. Future work must focus on rigorous clinical trials to validate these redox-targeted strategies in human patients.
Summary updated